Fengyun Hao

Fengyun Hao

Auto-generated profile, based on publicly available information

Fengyun Hao

Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2024 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
YHYongzheng Hu
Yongzheng Hu
FHFengyun Hao
Fengyun Hao
QAQian An
Qian An
WJWei Jiang
Wei Jiang
Prior research has established associations between immune cells, inflammatory proteins, and chronic kidney disease (CKD). Our Mendelian randomization study aims to elucidate the genetic causal relationships among these factors and CKD. We applied Mendelian randomization using genetic variants associated with CKD from a large genome-wide association study (GWAS) and inflammatory markers from a comprehensive GWAS summary. The causal links between exposures (immune cell subtypes and inflammatory proteins) and CKD were primarily analyzed using the inverse variance-weighted, supplemented by sensitivity analyses, including MR-Egger, weighted median, weighted mode, and MR-PRESSO. Our analysis identified both absolute and relative counts of CD28 + CD45RA + CD8 + T cell (OR = 1.01; 95% CI = 1.01–1.02; p < 0.001, FDR = 0.018) (OR = 1.01; 95% CI = 1.00–1.01; p < 0.001, FDR = 0.002), CD28 on CD39 + CD8 + T cell(OR = 0.97; 95% CI = 0.96–0.99; p < 0.001, FDR = 0.006), CD16 on CD14–CD16 + monocyte (OR = 1.02; 95% CI = 1.01–1.03; p < 0.001, FDR = 0.004) and cytokines, such as IL-17A(OR = 1.11, 95% CI = 1.06–1.16, p < 0.001, FDR = 0.001), and LIF-R(OR = 1.06, 95% CI = 1.02–1.10, p = 0.005, FDR = 0.043) that are genetically predisposed to influence the risk of CKD. Moreover, the study discovered that CKD itself may causatively lead to alterations in certain proteins, including CST5(OR = 1.16, 95% CI = 1.09–1.24, p < 0.001, FDR = 0.001). No evidence of reverse causality was found for any single biomarker and CKD. This comprehensive MR investigation supports a genetic causal nexus between certain immune cell subtypes, inflammatory proteins, and CKD. These findings enhance the understanding of CKD's immunological underpinnings and open avenues for targeted treatments.

2 May 2016 in British Journal of Biomedical Science
Verified
Journal Article
Closed access
JLJiansheng Li
Jiansheng Li
KZKejun Zhang
Kejun Zhang
XLXishuang Liu
Xishuang Liu
FHFengyun Hao
Fengyun Hao
ZLZiming Liu
Ziming Liu
ZWZhibin Wang
Zhibin Wang
Background: Patients with papillary thyroid cancer (PTC) and enlarged cervical lymph nodes (CLNs) are usually assessed by fine-needle aspiration biopsy cytology (FNAB-C). Thyroglobulin (Tg) is frequently detected in washout of fine-needle aspirates (FNA) of these lymph nodes. The aim of this study was to evaluate the accuracy of the measurement of FNAB-Tg in the washout of FNAB in combination with FNAB-C to detect CLN metastases in PTC. Methods: We retrospectively evaluated 163 surgically proven CLNs. Ultrasound-guided FNAB-C and FNAB-Tg measurements were performed and the ultrasound features were evaluated. Results: The sensitivity, specificity and accuracy of FNAB-C, FNAB-Tg and FNAB-C/FNAB-Tg in diagnosis of metastatic CLNs were 85.7, 87.8 and 71.6%, were 80.5, 87 and 82.8% and were 97.1, 96.3 and 95.7%, respectively. The diagnostic sensitivity, specificity and accuracy of FNAB-C/FNAB-Tg for metastatic CLNs was significantly higher than that of FNAB-C or FNAB-Tg alone (p < 0.01). Conclusion: Combined US-guided FNAB-C and FNAB-Tg can improve the accuracy for diagnosis of metastatic CLNs in patients with PTC.

30 January 2024
Verified
Preprint
Open access
PDF file
FHFengyun Hao
Fengyun Hao
KZKejun Zhang
Kejun Zhang
LNLiang Ning
Liang Ning
CSChong Sun
Chong Sun
Vemurafenib, one of the selective BRAF inhibitor, is less effective in BRAF-mutant thyroid cancer, including anaplastic thyroid cancer (ATC), the mechanisms of which are still lacking. Pseudopodium-enriched atypical kinase 1 (PEAK1) has been demonstrated to be upregulated in human malignancies. Enhanced PEAK1 expression facilitates tumor cell survival and chemoresistance. Here we investigated the role and mechanisms of targeting PEAK1 in reversing vemurafenib resistance in ATC 8505C cells. PEAK1 depletion alone promotes cell cycle arrest, but not affect cell apoptosis.PEAK1 depletion sensitized 8505C cells to vemurafenib by promoting cell cycle arrest and inducing cell apoptosis. Vemurafenib could quickly inhibit ERK phosphorylation (pERK1/2), but quickly reactivate pERK1/2 in 8505C cells. Vemurafenib could only quickly activate AKT phosphorylation (pAKT) and slightly activate phosphorylation JNK1/2(pJNK1/2). However, vemurafenib in combination with PEAK1 deletion inhibited reactivation of pERK1/2 and pAKT activation, and promoted pJNK1/2. Vemurafenib transiently and slightly upregulated pro-apoptotic PUMA and Bim expression, which was quickly disappeared with long time vemurafenib treatment. Combined PEAK1 depletion and Vemurafenib treatment upregulated JNK1/2-dependant Bim and AKT-dependant PUMA expression. PUMA and Bim upregulation is critical for vemurafenib induced apoptosis in presence of PEAK1 deletion. Vemurafenib resistance in 8505C cells is associated with PEAK1 activation, pERK1/2 re-activation, pJNK1/2 inactivation and AKT activation, resulting in the inhibition of AKT-dependent PUMA and pERK1/2-pJNK1/2-dependent Bim expression. PEAK1 depletion could inhibited both ERK1/2 and AKT signal and released PUMA and Bim from vemurafenib-treated cells, resulting in the enhancing cell apoptosis. Therefore, targeting PEAK1 may be an effective strategy to sensitize BRAF-mutant ATC to vemurafenib.